

Can the EUnetHTA HTA Core Model[®] For Pharmaceuticals Help to Ensure an Aligned View of Value?

Monday June 15 - Oslo

Panel 08

Moderator: Luciana Ballini

#HTAiOslo2015



Panellists

Finn Kristensen

EUnetHTA Secretariat Director, Danish Health and Medicines Authority, Denmark

Wim Goettsch

Lead Partner EUnetHTA JA2 WP5 on Rapid Assessments - ZIN, The Netherlands

Jamie Garside

Health Outcomes Manager – Roche Products Ltd.

Luciana Ballini


Chair of EUnetHTA Plenary Assembly – ASSR, Italy



EUnetHTA at HTAi



HTA Core Model



An aligned view of value

Why an aligned view of Value ?

- For an aligned assessment process?
- For aligned outcomes (decisions) ?
- For eliciting assessments/decisions when body of evidence sufficient ?
- For a shared view on evidence generation ?
- For common definitions of value AND of lack of value ?

HTA Core Model[®] and Value

A practical tool for EUnetHTA to implement transnational collaborative HTA work that:

- stems from a long and complex process of revision
- is aligned with a shared meaning of value

Intended for an aligned process of assessment of value
in order to avoid duplication

HTA Core Model[®] and Value

- Multidimensional view of value
- 9 domains and over 100 questions related to value
- Challenges of non technical / non clinical domains
- Interdependence of domains

Are most elements of value embedded in the Core Model ?

Should all domains be developed for the assessment of value at any stage of development of the technology ?

What does the HTA Core Model[®] do for Value

- Ensures transparency
- Ensures common assessment process (methods)
- Handles persisting uncertainty
- Aids evidence generation to demonstrate value
- In-built flexibility for future adjustments

Has it improved predictability ?

Is it fit to encompass future adjustments on value?

What does the HTA Core Model[®] do for Value

- Tested by non EUnetHTA research/HTA groups
- Tested by manufacturers
- Basis for common submission template and for Additional Evidence Generation

Does shared use of HTA Core Model facilitate sharing of information on value from product development to product assessment ?

HTA Core Model[®] implemented

- Not an academic /theoretical terms of reference
- **A working tool tested within:**
 - EUnetHTA collaboration at large
Finn Kristensen
 - Rapid Relative Effectiveness Assessment (REA)
Wim Goettsch
 - Manufacturer's assessment of developed technology
Jamie Garside

Summary of perspectives from the Panelists

Finn Kristensen

- An overview of the EUnetHTA Core Model & planned revisions
- EUnetHTA Core Model Benefits and limitations
- The model is not yet established amongst stakeholders

Wim Goettsch

- The REA experience to date
- Do we wish to develop an aligned view of value amongst HTA bodies, payers, Pharmaceutical industry and Regulators?
- The future approaches for rapid REA & potential for a common framework of value

Jamie Garside

- Roche experience of the EUnetHTA Core Model
- Examples of where broader value would be helpful in HTA assessments